Cibus (CBUS) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 06, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	CLXT
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		37,200,473
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38161
Entity Tax Identification Number	27-1967997
Entity Address, Address Line One	2800 Mount Ridge Road
Entity Address, City or Town	Roseville
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55113-1127
City Area Code	651
Local Phone Number	683-2807
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock (0.0001 par value)
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 16,386	$ 17,299
Short-term investments	3,045	11,698
Restricted cash	393	393
Accounts receivable	1,354	4,887
Inventory	4,532	1,383
Prepaid expenses and other current assets	3,347	3,930
Total current assets	29,057	39,590
Non-current restricted cash	597	597
Land, buildings, and equipment	22,549	22,860
Other non-current assets	225	280
Total assets	52,428	63,327
Current liabilities:
Accounts payable	959	929
Accrued expenses	3,058	2,891
Accrued compensation	1,764	1,950
Due to related parties	114	766
Current portion of financing lease obligations	372	364
Other current liabilities	45	45
Total current liabilities	6,312	6,945
Financing lease obligations	17,780	17,876
Long-term debt	1,518	1,518
Other non-current liabilities	1,213	113
Total liabilities	26,823	26,452
Stockholders’ equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 37,263,339 shares issued and 37,163,187 shares outstanding as of March 31, 2021, and 37,165,196 shares issued and 37,065,044 shares outstanding as of December 31, 2020	4	4
Additional paid-in capital	203,565	204,807
Common stock in treasury, at cost; 100,152 shares as of March 31, 2021, and December 31, 2020	(1,043)	(1,043)
Accumulated deficit	(176,921)	(166,893)
Total stockholders’ equity	25,605	36,875
Total liabilities and stockholders’ equity	$ 52,428	$ 63,327

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	37,263,339	37,165,196
Common stock, shares outstanding	37,163,187	37,065,044
Treasury stock, shares	100,152	100,152

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue	$ 4,402	$ 2,377
Cost of goods sold	6,745	3,884
Gross margin	(2,343)	(1,507)
Operating expenses:
Research and development	3,050	2,787
Selling, general, and administrative	4,258	6,298
Management fees and royalties	30	62
Total operating expenses	7,338	9,147
Loss from operations	(9,681)	(10,654)
Interest, net	(346)	(398)
Non-operating expenses	(1)	(11)
Loss before income taxes	(10,028)	(11,063)
Income taxes	0	0
Net loss	$ (10,028)	$ (11,063)
Basic and diluted net loss per share	$ (0.27)	$ (0.34)
Weighted average shares outstanding - basic and diluted	37,136,338	32,988,141
Anti-dilutive stock options, restricted stock units, and performance stock units	5,013,780	5,328,268

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2019	$ 62,508	$ 3	$ 185,588	$ (1,043)	$ (122,057)	$ 17
Beginning balance, shares at Dec. 31, 2019		32,951,329
Net loss	(11,063)				(11,063)
Stock-based compensation	1,271		1,271
Issuance of common stock, shares		57,110
Shares withheld for net share settlement, shares		(17,792)
Other comprehensive income (loss)	(180)					(180)
Ending balance at Mar. 31, 2020	52,536	$ 3	186,859	(1,043)	(133,120)	$ (163)
Ending balance, shares at Mar. 31, 2020		32,990,647
Beginning balance at Dec. 31, 2020	36,875	$ 4	204,807	(1,043)	(166,893)
Beginning balance, shares at Dec. 31, 2020		37,065,044
Net loss	(10,028)				(10,028)
Stock-based compensation	(1,450)		(1,450)
Issuance of common stock	208		208
Issuance of common stock, shares		98,143
Ending balance at Mar. 31, 2021	$ 25,605	$ 4	$ 203,565	$ (1,043)	$ (176,921)
Ending balance, shares at Mar. 31, 2021		37,163,187

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating activities
Net loss	$ (10,028)	$ (11,063)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	585	452
Stock-based compensation	(1,450)	1,271
Changes in operating assets and liabilities:
Accounts receivable	3,533	281
Due to/from related parties	(652)	(430)
Inventory	(3,149)	(604)
Prepaid expenses and other current assets	583	(786)
Accounts payable	30	8
Accrued expenses	167	(451)
Accrued compensation	(186)	(818)
Other non-current liabilities	1,100	(9)
Other	50	(89)
Net cash used by operating activities	(9,417)	(12,238)
Investing activities
Sales and (purchases) of short-term investments, net	8,653	(38,620)
Purchases of land, buildings, and equipment	(269)	(317)
Net cash provided by (used by) investing activities	8,384	(38,937)
Financing activities
Repayments of financing lease obligations	(88)	(45)
Proceeds from the exercise of stock options	208
Net cash provided by (used by) financing activities	120	(45)
Net decrease in cash, cash equivalents, and restricted cash	(913)	(51,220)
Cash, cash equivalents, and restricted cash - beginning of period	18,289	60,038
Cash, cash equivalents, and restricted cash – end of period	$ 17,376	$ 8,818

Basis of Presentation & Summary

Basis of Presentation & Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation & Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Our unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In our opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of our statements of financial position, results of operations, and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates. Certain prior year amounts have been reclassified to conform to the current year presentation. For further information, refer to the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 4, 2021. The accompanying Balance Sheet as of December 31, 2020, was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes included in the Annual Report on Form 10-K for the year ended December 31, 2020. Net Loss Per Share All anti-dilutive stock options, restricted stock units, and performance stock units are excluded from the calculation of net loss per share. Due to our net loss position for the three months ended March 31, 2021 and March 31, 2020, all of our outstanding stock options, restricted stock units, and performance stock units are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units.

Financial Instruments Measured

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	3 Months Ended
	Mar. 31, 2021
Text Block [Abstract]
Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	2. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE AND CONCENTRATIONS OF CREDIT RISK Financial Instruments Measured at Fair Value and Financial Statement Presentation Financial instruments including cash and cash equivalents, restricted cash, accounts payable, and all other current liabilities have carrying values that approximate fair value. We measure short-term investments and commodity derivative contracts at fair value on a recurring basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows: Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities. Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. Level 3: Fair values are based on at least one significant unobservable input for the asset or liability. Fair Value Measurements and Financial Statement Presentation The fair values of our financial instruments measured at fair value and their respective levels in the fair value hierarchy as of March 31, 2021, and December 31, 2020, were as follows: March 31, 2021 March 31, 2021 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 3,045 $ — $ — $ 3,045 $ — $ — $ — $ — Commodity derivative contracts 266 — — 266 — — — — Total $ 3,311 $ — $ — $ 3,311 $ — $ — $ — $ — December 31, 2020 December 31, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 11,698 $ — $ — $ 11,698 $ — $ — $ — $ — Commodity derivative contracts 467 — — 467 — — — — Total $ 12,165 $ — $ — $ 12,165 $ — $ — $ — $ — The non-current portion of our financing lease obligations are also considered a financial instrument, which we measure at fair value for disclosure purposes. It is a Level 2 liability and had a fair value of $15.1 million as of March 31, 2021, and a fair value of $15.2 million as of December 31, 2020. The composition of our short-term investments as of March 31, 2021, and December 31, 2020 were as follows: As of March 31, As of December 31, In Thousands 2021 2020 Corporate debt securities $ 3,045 $ 11,698 Commodity Price Risk We enter into seed and grain production agreements with settlement values based on commodity futures market prices (Forward Purchase Contracts). These Forward Purchase Contracts allow the counterparty to fix their sales prices at various times as defined in the contract. Because we intend to take physical delivery under the Forward Purchase Contracts, we have grain inventory we will need to sell. We intend to sell these inventories at then-current market prices. As a result, when the Forward Purchase Contract counterparty fixes their grain prices, we enter hedging arrangements by selling futures contracts which converts our exposure to these fixed prices to floating prices. We expect to maintain these hedging relationships until such grain inventory is sold to help stabilize our margins. We do not account for these economic hedges as accounting hedges. We expect any gains or losses from these hedging arrangements to be offset by gains or losses on the grain inventories when such grain inventories are sold. We previously designated all our commodity derivative contracts as cash flow hedges based on the nature of our business activities under the prior go-to-market strategy. As a result, all gains or losses associated with recording those commodity derivative contracts at fair value were recorded as a component of accumulated other comprehensive income (loss) (AOCI). We reclassify amounts from AOCI to cost of goods sold when we sell the underlying products to which those hedges relate. For the three months ended March 31, 2020, we reclassified an immaterial amount from AOCI to cost of goods sold, and there were no such reclassifications in the same period in 2021. Foreign Exchange Risk Foreign currency fluctuations affect our foreign currency cash flows related primarily to payments to Cellectis. Our principal foreign currency exposure is to the euro. We do not hedge these exposures, and we do not believe that the current level of foreign currency risk is significant to our operations. Concentrations of Credit Risk We invest our cash, cash equivalents, and restricted cash in highly liquid securities and investment funds. We diversify this risk by allocating our investments to a diverse portfolio of short-dated, high investment-grade securities we classify as short-term investments that are recorded at fair value in our consolidated financial statements. We ensure the credit risk in this portfolio is in accordance with our internal policies and if necessary, make changes to investments to ensure credit risk is minimized. We have not experienced any counterparty credit losses.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	3. RELATED-PARTY TRANSACTIONS We have several agreements that govern our relationship with Cellectis, some of which require us to make payments to Cellectis. Pursuant to our management services agreement with Cellectis, we incurred nominal management fee expenses Cellectis has also guaranteed the lease agreement for our headquarters. Cellectis’ guarantee of our obligations under the lease will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $300 million. TALEN ® ® ® We have incurred nominal license and royalty fees We have entered into various agreements with the University of Minnesota, pursuant to which we have been granted both exclusive and non-exclusive license agreements that carry annual license fees, milestone payments, royalties, and associated legal fees. These agreements primarily relate to gene-editing tools, enabling technologies and germplasm. We incurred nominal expenses pursuant to these agreements for the three months ended March 31, 2021 and March 31, 2020.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	4. We use broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of our shareholders. We have also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis. In December 2014, we adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, we adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, restricted stock units, performance stock units and other types of equity awards. On February 19, 2021, James Blome ceased serving as our Chief Executive Officer. We recorded a benefit to earnings from a $2.5 million recapture of non-cash stock compensation expense from the forfeiture of certain of Mr. Blome’s unvested stock options, restricted stock units, and performance stock units. As of March 31, 2021, 1,902,128 shares were registered and available for grant under effective registration statements, while 6,202,032 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan, under which no further awards will be granted. Stock Options The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Three Months Ended March 31, 2021 2020 Estimated fair values of stock options granted $ 5.85 $ 5.19 Assumptions: Risk-free interest rate 0.6 % 1.7 % Expected volatility 85.0 % 77.4 % Expected term (in years) 5.7 - 6.2 6.9 We estimate the fair value of each option on the grant date, or other measurement dates if applicable, using a Black-Scholes option-pricing model, which requires us to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. Our expected term represents the period that options granted are expected to be outstanding determined using the simplified method. We estimate our future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. We estimate the risk-free interest rate based on the United States Treasury zero-coupon yield curve at the date of grant for the expected term of the option. We do not nor do we expect to pay dividends. Option strike prices are set at 100 percent or more of the closing share price on the date of grant, and generally vest over three to six years following the grant date. Options generally expire 10 years after the date of grant. Information on stock option activity is as follows: Options Exercisable Weighted- Average Exercise Price Per Share Options Outstanding Weighted- Average Exercise Price Per Share Balance as of December 31, 2020 2,347,663 $ 10.15 4,621,173 $ 10.30 Granted 270,800 8.07 Exercised (56,372 ) 3.71 Forfeited or expired (456,450 ) 10.03 Balance as of March 31, 2021 2,369,997 $ 10.38 4,379,151 $ 10.27 Stock-based compensation expense related to stock option awards is as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock-based compensation expense $ (396 ) $ 1,006 As of March 31, 2021, options outstanding and exercisable had an aggregate intrinsic value of $2.2 million and the weighted average remaining contractual term was 6.0 years. Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended March 31, In Thousands 2021 2020 Net cash proceeds $ 208 $ — Intrinsic value of options exercised $ 331 $ — As of March 31, 2021, unrecognized compensation expense related to non-vested stock options was $6.9 million. This expense will be recognized over 30 Restricted Stock Units Units settled in stock subject to a restricted period may be granted under the 2017 Plan. Restricted stock units generally vest and become unrestricted over three to five years after the date of grant. Information on restricted stock unit activity is as follows: Number of Restricted Stock Units Outstanding Weighted- Average Grant Date Fair Value Unvested balance at December 31, 2020 547,807 $ 9.49 Granted 68,000 8.05 Vested (27,386 ) 9.18 Forfeited (126,178 ) 12.89 Unvested balance at March 31, 2021 462,243 $ 8.37 The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended March 31, In Thousands 2021 2020 Grant-date fair value $ 251 $ 510 Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock-based compensation expense $ (749 ) $ 155 As of March 31, 2021, unrecognized compensation expense related to restricted stock units was $1.7 million. This expense will be recognized over 27 months on average. We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows: Three Months Ended March 31, In Thousands 2021 2020 Deemed dividends from grants to Cellectis employees $ 79 $ 224 Performance Stock Units In June 2019, we granted 311,667 performance stock units under the 2017 Plan to three executive officers. three-year Stock-based compensation expense related to performance stock units is as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock-based compensation expense $ (305 ) $ 110 As of March 31, 2021, unrecognized compensation expense related to performance stock units was $0.7 million. This expense will be recognized over 39 months on average.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	5. INCOME TAXES We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. As of March 31, 2021 , there were no material changes to what we disclosed regarding tax uncertainties or penalties as of December 31, 2020 .

Leases, Other Commitments, and

Leases, Other Commitments, and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Leases, Other Commitments, and Contingencies	6. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES Litigation and Claims We are not currently a party to any material pending legal proceeding. Leases We lease our headquarters facility, office equipment, and other items. Our headquarters lease involved the sale of land and improvements to a third party who then constructed the facility. This lease is considered a financing lease. We also have an equipment financing arrangement that is considered a financing lease. This arrangement has a term of four years for each draw. We were required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of March 31, 2021, restricted cash totaled $1.0 million. We have the option to request the return of excess collateral annually in December, and the amount we expect to receive is reflected as a current asset. Rent expense from operating leases was as follows: Three Months Ended March 31, In Thousands 2021 2020 Rent expense from operating leases $ 13 $ 24 Other Commitments As of March 31, 2021, we have noncancelable commitments to purchase grain and seed from growers at dates throughout 2021 aggregating $11.7 million based on current commodity futures market prices, other payments to growers, and estimated yields per acre. This commitment is not recorded in the consolidated financial statements because we have not taken delivery of the seed or grain as of March 31, 2021.

Supplemental Information

Supplemental Information	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Information	7. SUPPLEMENTAL INFORMATION Certain balance sheet amounts are as follows: As of March 31, As of December 31, In Thousands 2021 2020 Accounts Receivable: Accounts receivable $ 1,107 $ 4,317 Receivables from growers 247 570 Allowance for doubtful accounts — — Total $ 1,354 $ 4,887 We carry receivables related to amounts we are owed by growers from their purchases of seed. These amounts reduce the cost of the grain we ultimately purchase from the grower and are repaid either on current terms or on an extended payment basis. If a grower has elected extended payment terms, they will pay a higher price per unit and grant us the right to deduct the amount we are owed from the payment we make upon the purchase of their grain. As of March 31, 2021 and December 31, 2020 all of the receivables from growers were on extended payment terms. Certain statements of operations amounts are as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock compensation expense: Research and development $ 392 $ 319 Selling, general, and administrative (1,842 ) 952 Total $ (1,450 ) $ 1,271 Three Months Ended March 31, In Thousands 2021 2020 Interest, net: Interest expense $ (360 ) $ (372 ) Interest income 14 (26 ) Total $ (346 ) $ (398 ) Certain statements of cash flows amounts are as follows: As of March 31, In Thousands 2021 2020 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 16,386 $ 7,385 Restricted cash 393 388 Non-current restricted cash 597 1,045 Total cash, cash equivalents, and restricted cash 17,376 8,818 Short-term investments 3,045 38,620 Total $ 20,421 $ 47,438

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	8 . SEGMENT INFORMATION We operate in a single

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt	9. LONG-TERM DEBT Our long-term debt is comprised of a $1.5 million promissory note pursuant to the Paycheck Protection Program (the Paycheck Protection Program loan) established by the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) implemented by the U.S. Small Business Administration (SBA). We received the funds under the Paycheck Protection Program loan on April 19, 2020. The Paycheck Protection Program loan matures in April 2022 and bears interest at a per annum rate of one percent. The Paycheck Protection Program loan may be prepaid at any time prior to maturity with no prepayment penalties. The Paycheck Protection Program loan contains customary events of default relating to, among other things, payment defaults and breaches of representations and We have applied the proceeds from the Paycheck Protection Program loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, we applied for forgiveness of the full principal amount and all accrued interest, and o n April 8, 2021, we were notified by the SBA that the full amount of our Paycheck Protection Program loan had been forgiven. We expect to record income in the second quarter of 2021 for the full amount of the loan and the associated accrued interest.

Basis of Presentation & Summa_2

Basis of Presentation & Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Net Loss Per Share	Net Loss Per Share All anti-dilutive stock options, restricted stock units, and performance stock units are excluded from the calculation of net loss per share. Due to our net loss position for the three months ended March 31, 2021 and March 31, 2020, all of our outstanding stock options, restricted stock units, and performance stock units are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units.

Financial Instruments Measure_2

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk (Tables)	3 Months Ended
	Mar. 31, 2021
Text Block [Abstract]
Summary of Fair Value Measurements and Financial Statement Presentation	The fair values of our financial instruments measured at fair value and their respective levels in the fair value hierarchy as of March 31, 2021, and December 31, 2020, were as follows: March 31, 2021 March 31, 2021 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 3,045 $ — $ — $ 3,045 $ — $ — $ — $ — Commodity derivative contracts 266 — — 266 — — — — Total $ 3,311 $ — $ — $ 3,311 $ — $ — $ — $ — December 31, 2020 December 31, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 11,698 $ — $ — $ 11,698 $ — $ — $ — $ — Commodity derivative contracts 467 — — 467 — — — — Total $ 12,165 $ — $ — $ 12,165 $ — $ — $ — $ —
Composition of Short-term Investments	The composition of our short-term investments as of March 31, 2021, and December 31, 2020 were as follows: As of March 31, As of December 31, In Thousands 2021 2020 Corporate debt securities $ 3,045 $ 11,698

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model	The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Three Months Ended March 31, 2021 2020 Estimated fair values of stock options granted $ 5.85 $ 5.19 Assumptions: Risk-free interest rate 0.6 % 1.7 % Expected volatility 85.0 % 77.4 % Expected term (in years) 5.7 - 6.2 6.9
Summary of Stock Option Activity	Information on stock option activity is as follows: Options Exercisable Weighted- Average Exercise Price Per Share Options Outstanding Weighted- Average Exercise Price Per Share Balance as of December 31, 2020 2,347,663 $ 10.15 4,621,173 $ 10.30 Granted 270,800 8.07 Exercised (56,372 ) 3.71 Forfeited or expired (456,450 ) 10.03 Balance as of March 31, 2021 2,369,997 $ 10.38 4,379,151 $ 10.27
Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised	Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended March 31, In Thousands 2021 2020 Net cash proceeds $ 208 $ — Intrinsic value of options exercised $ 331 $ —
Summary of Activity of Restricted Stock Units	Information on restricted stock unit activity is as follows: Number of Restricted Stock Units Outstanding Weighted- Average Grant Date Fair Value Unvested balance at December 31, 2020 547,807 $ 9.49 Granted 68,000 8.05 Vested (27,386 ) 9.18 Forfeited (126,178 ) 12.89 Unvested balance at March 31, 2021 462,243 $ 8.37
Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested	The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended March 31, In Thousands 2021 2020 Grant-date fair value $ 251 $ 510
Summary of Stock-Based Compensation Granted As Deemed Dividends	We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows: Three Months Ended March 31, In Thousands 2021 2020 Deemed dividends from grants to Cellectis employees $ 79 $ 224
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to stock option awards is as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock-based compensation expense $ (396 ) $ 1,006
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock-based compensation expense $ (749 ) $ 155
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to performance stock units is as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock-based compensation expense $ (305 ) $ 110

Leases, Other Commitments, an_2

Leases, Other Commitments, and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Lease Cost [Abstract]
Summary of Rent Expense from Operating Leases	Rent expense from operating leases was as follows: Three Months Ended March 31, In Thousands 2021 2020 Rent expense from operating leases $ 13 $ 24

Supplemental Information (Table

Supplemental Information (Tables)	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Certain Balance Sheet Amounts	Certain balance sheet amounts are as follows: As of March 31, As of December 31, In Thousands 2021 2020 Accounts Receivable: Accounts receivable $ 1,107 $ 4,317 Receivables from growers 247 570 Allowance for doubtful accounts — — Total $ 1,354 $ 4,887
Schedule of Certain Statements of Operations Amounts	Certain statements of operations amounts are as follows: Three Months Ended March 31, In Thousands 2021 2020 Stock compensation expense: Research and development $ 392 $ 319 Selling, general, and administrative (1,842 ) 952 Total $ (1,450 ) $ 1,271 Three Months Ended March 31, In Thousands 2021 2020 Interest, net: Interest expense $ (360 ) $ (372 ) Interest income 14 (26 ) Total $ (346 ) $ (398 )
Schedule of Statements of Certain Statements of Cash Flows Amounts	Certain statements of cash flows amounts are as follows: As of March 31, In Thousands 2021 2020 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 16,386 $ 7,385 Restricted cash 393 388 Non-current restricted cash 597 1,045 Total cash, cash equivalents, and restricted cash 17,376 8,818 Short-term investments 3,045 38,620 Total $ 20,421 $ 47,438

Financial Instruments Measure_3

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 3,311	$ 12,165
Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	3,045	11,698
Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	266	467
Level 1 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	3,311	12,165
Level 1 [Member] | Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	3,045	11,698
Level 1 [Member] | Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 266	$ 467

Financial Instruments Measure_4

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair value of financing leases	$ 15.1	$ 15.2
Commodity Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Commodity derivative assets, notional amount	10.4
Unrealized commodity derivative losses from hedging contracts sold	$ 3

Financial Instruments Measure_5

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Composition of Short-term Investments (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Total short-term investments	$ 3,045	$ 11,698	$ 38,620
Corporate Debt Securities [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Total short-term investments	$ 3,045	$ 11,698

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail)	Mar. 31, 2021USD ($)
Cellectis [Member]
Related Party Transaction [Line Items]
Minimum net worth required	$ 300,000,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2021	Feb. 19, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	1,902,128
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	6,202,032
Mr. Blome [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected benefit to earnings from recapture of non-cash stock compensation expense		$ (2.5)

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 5.85	$ 5.19
Risk-free interest rate	0.60%	1.70%
Expected volatility	85.00%	77.40%
Expected term (in years)		6 years 10 months 24 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 8 months 12 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 2 months 12 days

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options	$ 6,900,000
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, percent	100.00%
Stock option expiration period	10 years
Weighted average remaining contractual term	6 years
Aggregate intrinsic value of options outstanding and exercisable	$ 2,200,000
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	6 years
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expect to pay dividends	$ 0
Unrecognized stock-based compensation expense, expected recognition weighted-average period	30 months

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Exercisable, Beginning Balance | shares	2,347,663
Options Exercisable, Ending Balance | shares	2,369,997
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 10.15
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 10.38
Options Outstanding, Beginning Balance | shares	4,621,173
Options Outstanding, Granted | shares	270,800
Options Outstanding, Exercised | shares	(56,372)
Options Outstanding, Forfeited or expired | shares	(456,450)
Options Outstanding, Ending Balance | shares	4,379,151
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 10.30
Weighted-Average Exercise Price Per Share, Granted | $ / shares	8.07
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	3.71
Weighted-Average Exercise Price Per Share, Forfeited or expired | $ / shares	10.03
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 10.27

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (1,450)	$ 1,271
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (396)	$ 1,006

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Net cash proceeds	$ 208
Intrinsic value of options exercised	$ 331

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 1.7
Unrecognized stock-based compensation expense, expected recognition weighted-average period	27 months
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance | shares	547,807
Number of restricted stock units outstanding, Granted | shares	68,000
Number of restricted stock units outstanding, Vested | shares	(27,386)
Number of restricted stock units outstanding, Forfeited | shares	(126,178)
Number of restricted stock units outstanding, Unvested ending balance | shares	462,243
Weighted-average grant date fair value, Unvested beginning balance | $ / shares	$ 9.49
Weighted-average grant date fair value, Granted | $ / shares	8.05
Weighted-average grant date fair value, Vested | $ / shares	9.18
Weighted-average grant date fair value, Forfeited | $ / shares	12.89
Weighted-average grant date fair value, Unvested ending balance | $ / shares	$ 8.37

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 251	$ 510

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (1,450)	$ 1,271
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (749)	$ 155

Stock-Based Compensation - Su_8

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Nonemployee Restricted Stock Units [Member] | Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employees	$ 79	$ 224

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		1,902,128
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		6,202,032
Performance Stock Units [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Increase in common stock starting price	$ 12.48
Unrecognized stock-based compensation expense related to performance stock units		$ 0.7
Unrecognized stock-based compensation expense, expected recognition weighted-average period		39 months
Performance Stock Units [Member] | Tranche One [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50.00%
Performance Stock Units [Member] | Tranche Two [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	100.00%
Performance Stock Units [Member] | Tranche Three [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	120.00%
Performance Stock Units [Member] | Mr. Blome [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Benefit from forfeiture of stock		166,667
Performance Stock Units [Member] | Three Executive Officers [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	311,667

Stock-Based Compensation - Su_9

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Performance Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (1,450)	$ 1,271
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (305)	$ 110

Leases, Other Commitments, an_3

Leases, Other Commitments, and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Other Commitments [Line Items]
Restricted cash	$ 393	$ 388
Forward purchase noncancelable commitments amount	$ 11,700
Equipment [Member]
Other Commitments [Line Items]
Lease term	4 years
Restricted cash	$ 1,000

Leases, Other Commitments, an_4

Leases, Other Commitments, and Contingencies - Summary of Rent Expense from Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Leases Rent Expense [Abstract]
Rent expense from operating leases	$ 13	$ 24

Supplemental Information - Summ

Supplemental Information - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accounts Receivable:
Accounts receivable	$ 1,107	$ 4,317
Total	1,354	4,887
Growers [Member]
Accounts Receivable:
Accounts receivable	$ 247	$ 570

Supplemental Information - Su_2

Supplemental Information - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ (1,450)	$ 1,271
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	392	319
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ (1,842)	$ 952

Supplemental Information - Su_3

Supplemental Information - Summary of Components of Interest, Net (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Interest expense	$ (360)	$ (372)
Interest income	14	(26)
Total	$ (346)	$ (398)

Supplemental Information - Su_4

Supplemental Information - Summary of Statements of Certain Statements of Cash Flows Amounts (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Cash and cash equivalents	$ 16,386	$ 17,299	$ 7,385
Restricted cash	393		388
Non-current restricted cash	597	597	1,045
Total cash, cash equivalents, and restricted cash	17,376	18,289	8,818	$ 60,038
Short-term investments	3,045	$ 11,698	38,620
Total	$ 20,421		$ 47,438

Segment Information - Additiona

Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021Segment
Segment Reporting [Abstract]
Number of reportable segment	1

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - Paycheck Protection Program Loan CARES Act [Member] - USD ($)	Apr. 08, 2021	Apr. 19, 2020	Mar. 31, 2021
Debt Instrument [Line Items]
Loan, face amount		$ 1,500,000
Loan, interest rate		1.00%
Loan, maturity date		2022-04
Prepayment penalties		$ 0
Forgiveness eligibility description			In order to be eligible for forgiveness, the proceeds of the Paycheck Protection Program loan must be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40 percent of the amount applied to non-payroll costs.
Subsequent Event [Member]
Debt Instrument [Line Items]
Description of loan forgiveness status	We have applied the proceeds from the Paycheck Protection Program loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, we applied for forgiveness of the full principal amount and all accrued interest, and on April 8, 2021, we were notified by the SBA that the full amount of our Paycheck Protection Program loan had been forgiven. We expect to record income in the second quarter of 2021 for the full amount of the loan and the associated accrued interest.